Cara Therapeutics (GB:0HTC)
UK Market

Cara Therapeutics Stock Analysis & Ratings

GB:0HTC Stock Chart & Stats

Day’s Range$8.59 - $8.585
52-Week Range$0.00 - $0.00
Previous Close$8.31
Average Volume (3M)134.00
Market Cap$460.08M
P/E RatioN/A
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)0.00



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest stock price was $0.00 and its highest was $0.00 in the past 12 months.
    What is Cara Therapeutics’s market cap?
    Cara Therapeutics’s market cap is $460.08M.
      What is Cara Therapeutics’s price target?
      The average price target for Cara Therapeutics is $26.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $30.00 ,the lowest forecast is $19.00. The average price target represents 202.85% Increase from the current price of $8.585.
        What do analysts say about Cara Therapeutics?
        Cara Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Cara Therapeutics’s upcoming earnings report date?
          Cara Therapeutics’s upcoming earnings report date is Aug 09, 2022 which is in 80 days.
            How were Cara Therapeutics’s earnings last quarter?
            Cara Therapeutics released its earnings results on May 09, 2022. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.031.
              Is Cara Therapeutics overvalued?
              According to Wall Street analysts Cara Therapeutics’s price is currently Undervalued.
                Does Cara Therapeutics pay dividends?
                Cara Therapeutics does not currently pay dividends.
                What is Cara Therapeutics’s EPS estimate?
                Cara Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Cara Therapeutics have?
                Cara Therapeutics has 53,590,000 shares outstanding.
                  What happened to Cara Therapeutics’s price movement after its last earnings report?
                  Cara Therapeutics reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went up 20.062%.
                    Which hedge fund is a major shareholder of Cara Therapeutics?
                    Among the largest hedge funds holding Cara Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Cara Therapeutics’s shares valued at 30M.


                      Cara Therapeutics Stock Analysis

                      The Cara Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Cara Therapeutics

                      CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.

                      Similar Stocks
                      Price & Change
                      Assertio Therapeutics
                      Collegium Pharmaceutical
                      Pacira Pharmaceuticals

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis